University of Cambridge Archives - CanPath - Canadian Partnership for Tomorrow’s Health

CanPath – Canadian Partnership for Tomorrow’s Health Search

About Us
- Purpose, Vision & Mission
  CanPath is working in partnership to prevent disease and provide a platform for scientists to conduct innovative research.
- Our History
  The Canadian Partnership Against Cancer established the Canadian Partnership for Tomorrow Project (now CanPath) in June 2008.
- Leadership & Governance
  Meet the members of CanPath's Leadership Team, Operations Committee, National Strategic Advisory Council and more.
- National Coordinating Centre
  Meet the members of CanPath's operational core, based at the University of Toronto's Dalla Lana School of Public Health.
- Regional Cohorts
  Seven regional cohorts across ten provinces comprise CanPath's pan-Canadian partnership.
- Funders & Supporters
  Learn more about the partner organizations that provide funding and in-kind support to CanPath.
- Frequently Asked Questions
  Find out how CanPath will improve the health of Canadians and more.
- Contact us
  How to reach CanPath by phone, email, in-person, or make a data access request.
Research
- About the Study
  CanPath is Canada’s largest population health cohort and a gateway platform to data worldwide.
- Access Process
  The CanPath Access Portal provides researchers with the necessary resources to identify epidemiological and biological data available from participating cohorts to answer innovative research questions.
- Approved Projects & Studies
  CanPath has supported more than 100 research projects and activities, many of which have resulted in publications in high impact journals.
- Publications
  These publications are examples of research made possible with data from CanPath and its regional cohorts.
- Funding & Grant Opportunities
- COVID-19 Initiatives
  As Canada’s largest population health study, CanPath responded quickly to the pandemic by leveraging its existing infrastructure to support national COVID-19 research.
- Student Dataset
  CanPath's Student Dataset provides students the unique opportunity to gain hands-on experience working with CanPath data.
- Collaborations
  The CanPath team is committed to collaborating with partners in order to enhance and accelerate research for a healthier Canada.
Participants
- About the Study
  CanPath is Canada’s largest population health cohort and a gateway platform to data worldwide.
- Participant Snapshot
  Understand the unique social, economic and health characteristics of CanPath participants and how this information is captured for research.
- Meet CanPath Participants
  Hundreds of thousands of Canadians have come together to be part of a study that reveals real breakthroughs.
- COVID-19 Antibody Study FAQ
  CanPath and its regional cohorts are conducting a COVID-19 antibody study of 20,000 participants across Canada.
News & Events
CanPath Access Portal

Newest to Oldest
Oldest to Newest

2021

A functionally impaired missense variant identified in French Canadian families implicates FANCI as a candidate ovarian cancer-predisposing gene

Authors: Caitlin T. Fierheller, Laure Guitton-Sert, Wejdan M. Alenezi, Timothée Revil, Kathleen K. Oros, Yuandi Gao, Karine Bedard, Suzanna L. Arcand, Corinne Serruya, Supriya Behl, Liliane Meunier, Hubert Fleury, Eleanor Fewings, Deepak N. Subramanian, Javad Nadaf, Jeffrey P. Bruce, Rachel Bell, Diane Provencher, William D. Foulkes, Zaki El Haffaf, Anne-Marie Mes-Masson, Jacek Majewski, Trevor J. Pugh, Marc Tischkowitz, Paul A. James, Ian G. Campbell, Celia M. T. Greenwood, Jiannis Ragoussis, Jean-Yves Masson, Patricia N. Tonin

Researchers sought to describe how new genes might be associated with ovarian cancer risk amongst 5,249 CARTaGENE participants. They found that a FANCI gene mutation is more common in familial ovarian cancer patients.

Read Publication

2014

Conditions Associated with Circulating Tumor-Associated Folate Receptor 1 Protein in Healthy Men and Women

Authors: Linda Keleman, James Brenton, Christine Parkinson, Hayley Whitaker, Anna Piskorz, Ilona Csizmadi, Paula Robson

This article examined how FOLR1 protein could potentially be way to detect early cancer. The team used electrochemical luminescence immunoassay. The study concluded that they should use caution when saying that serum FOLR1 can detect early cancer as there has not been a study with enough evidence to truly determine that.

Read Publication